Can palbociclib be reimbursed by medical insurance?

After the original drug of Palbociclib (Palbociclib) was launched in China, it has passed the relevant policies of the National Medical Insurance Administration and entered the scope of Class B medical insurance, but it is limited to hormone receptor (HR) positive, human epidermal growth factor Patients with sub-receptor 2 (HER2)-negative locally advanced or metastatic breast cancer will be reimbursed. Patients who do not meet the conditions can only purchase it at their own expense. The price of each box may be more than 4,000 yuan. The reimbursement ratio is different in different regions, and the price after reimbursement may be different. Palbociclib has been approved overseas by the US Food and Drug Administration for the first-line treatment of HR+/HER2 breast cancer.